Back to the program

Contributed Papers

Dose Finding & Dose Optimization

Wed, Aug 5, 2:00 PM - 3:50 PM Room CC-204A Thomas M. Menino Convention & Exhibition Center

Susan MayoChair

Biopharmaceutical Section

7 Presentations

A Bayesian design for dual-agent dose optimization with targeted therapies

2:05 PM - 2:20 PM

Mourad Tighiouart (Cedars-Sinai Medical Center)

Co-authors: Jose Luis Jimenez

Bayesian phase I-II design Dose optimization Drug combination Oncology Targeted therapies

A Discussion of Design Strategies for Dose Optimization and Confirmatory Phase

2:20 PM - 2:35 PM

Xiaochen Zhu (BMS)

Co-authors: Annan Deng (New York University School of Medicine), YIWEI LI, Haiyang Sheng (Bristol Myers Squibb), Tian Chen (BMS), Shu-Pang Huang (NCSU)

Dose optimization Oncology clinical trial Seamless design

A Novel Analysis Approach for Randomized Clinical Trials with Placebo and Two Dose Levels

2:35 PM - 2:50 PM

Devan Mehrotra (Merck & Co., Inc.)

Co-authors: Fang Liu (Merck & Co., Inc.)

dose-response linearization model averaging pairwise comparison

A Phase I Dose-finding Design Incorporating Intra-patient Dose Escalation

2:50 PM - 3:05 PM

Suyu Liu (UT MD Anderson Cancer Center)

Co-authors: Beibei Guo (LSU Experimental Statistics)

dose finding intra-patient CRM

Function-Anchored Smoothing Shrinkage: Robust Bayesian Dose-Response Estimation for Dose Optimization

3:05 PM - 3:20 PM

Co-authors: Emine Bayman, Gideon Zamba (University of Iowa)

Bayesian semiparametric Function-anchored shrinkage Model misspecification

M-DODII: Bayesian dose optimization design for randomized phase II study with multiple indications

3:20 PM - 3:35 PM

Sasha Amdur Kravets (Eli Lilly and Company)

Co-authors: Ziji Yu (Takeda Pharmaceuticals), Rachael Liu (BMS), Jianchang Lin (Takeda)

Dose optimization Project Optimus Bayesian adaptive design Master protocol

Two-dose vs. Three-dose Optimization Under Sample Size Constraint

3:35 PM - 3:50 PM

Yixin Ren (Merck)

Co-authors: Linda Zhiping Sun, Cong Chen (Merck & Co., Inc.)

Dose selection Project Optimus Early endpoint

↑